The objective of this project is to develop a new method for in vitro chemosensitivity and chemoresistance testing of cancer. Phase I will be concerned with an in vitro cell culture system to develop the method, based upon the use of short-term culture of extirpated tumor cells, monitoring the effects of chemotherapeutic drugs on cell proliferation by means of the immunofluorescent detection of bromodeoxyuridine as a measure of DNA synthesis. In order to discriminate tumor cells from the normal diploid stromal cells in the culture, the karyotype of the interphase tumor cells will be will be predetermined by in situ fluorescence hybridation (FISH) prior to BrdUrd pulsing of the cultures, and FISH then performed on the BrdUrd-labeled cells. The dual fluorescence image analysis of IdUrd incorporation and selected FISH probes will distinguish the tumor cells from non-tumor cells in the culture. Corroboration of the identity of tumor cells will be made by a cytopathologist. The method combines the assessment of drug sensitivity of the tumor with the prognostic power of karyotyping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43CA061410-01
Application #
3493476
Study Section
Special Emphasis Panel (ZRG7-SSS-Z (04))
Project Start
1993-09-30
Project End
1994-03-30
Budget Start
1993-09-30
Budget End
1994-03-30
Support Year
1
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Oncyte, Inc.
Department
Type
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77054